Markets

Agenus (AGEN) Reports Narrower than Expected Loss in Q2

Agenus (AGEN) Reports Narrower than Expected Loss in Q2

Agenus Inc.AGEN is a Lexington, MA-based development-stage company focused on the discovery and development of checkpoint modulators, vaccines and adjuvants for the treatment of cancer.

The company earns revenues primarily through fees received under collaboration and license agreements, which not only provide it with funds in the form of upfront and milestone payments and future royalties, but also validate the company's proprietary product platform.

With no approved product in its portfolio yet, investor focus should remain on pipeline updates by the company. Agenus utilizes several platforms and programs for the development of its candidates - Retrocyte Display and SECANT technologies; antibody programs including checkpoint modulators (CPMs); vaccines program such as Prophage and AutoSynVax; and saponin-based vaccine adjuvants including QS-21 Stimulon adjuvant (QS-21 Stimulon). Additionally, the company expanded its antibody discovery platform by acquiring key antibody asset from Celexion.

Agenus' track record has been mixed so far. The company has surpassed estimates once in the trailing four quarters and missed the same on two occasion and was in line on one occasion, bringing the average surprise to -15.97%.

Currently, Agenus has a Zacks Rank #4 (Sell), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Agenus reported a loss of 24 cents in the second quarter of 2018 which was narrower than both the consensus loss estimate of 38 cents per share, and a loss of 32 cents reported a year ago.

Revenue: Revenues beat expectations in the quarter. Agenus posted revenues of $15.9 million, compared to our consensus estimate of $2 million.

Share Price Impact: Shares rose 2.8% in pre-market trading .

Agenus Inc. Price and EPS Surprise

Agenus Inc. Price and EPS Surprise | Agenus Inc. Quote

Check back later for our full write up on AGEN earnings report later!

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Agenus Inc. (AGEN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AGEN

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More